PRKAA2 and cardiomyopathy: Few models also revealed an involvement of AMPK in the development of cardiomyopathy [whole body AMPKα2 KO (Zarrinpashneh et al., 2008); muscle-specific AMPKβ1β2 KO (Sung et al., 2015)] and in cardiac oxidative capacity [whole body AMPKα2 KO (Athea et al., 2007)].